Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bovine thrombin Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography

NCT02448901
View directory record Official record
Conditions
Heart Failure
Interventions
Edoxaban
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

NCT01754480
View directory record Official record
Conditions
Parenchymous Tissue Surgical Bleeding
Interventions
Fibrin Sealant Grifols, Surgicel®
Biological · Device
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

HEMOBLAST Pivotal Clinical Investigation

NCT02780869
View directory record Official record
Conditions
Hemostasis
Interventions
HEMOBLAST Bellows, Absorbable gelatin sponge, USP with thrombin
Device
Lead sponsor
Biom'Up France SAS
Industry
Eligibility
21 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery

NCT00196534
View directory record Official record
Conditions
Cardiovascular, Neurologic (Spine), and General Surgery
Interventions
Human Thrombin, Bovine Thrombin
Drug
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2007 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

NCT02239120
View directory record Official record
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 150 Years
Enrollment
5,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

NCT01731938
View directory record Official record
Conditions
Soft Tissue Surgical Bleeding
Interventions
Fibrin Sealant (FS) Grifols, Surgicel®
Biological · Device
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
Not listed
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Florence, Alabama • Pasadena, California • Bridgeport, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 8:45 AM EDT
Terminated Phase 2 Interventional

Long Term Open Follow-up With H376/95 vs. Warfarin

NCT00206063
View directory record Official record
Conditions
Stroke Prevention in Patients With Atrial Fibrillation
Interventions
EXANTA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

The Fibrin Pad Cardiovascular Study

NCT01681030
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
EVARREST™, Topical hemostat, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty

NCT01410240
View directory record Official record
Conditions
Knee Replacement Surgery, Osteoarthritis
Interventions
Standard of Care, FLOSEAL Hemostatic Matrix + Standard of care
Procedure · Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 3 Interventional

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

NCT04563520
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, FEIBA, rFVIIa
Drug
Lead sponsor
Emory University
Other
Eligibility
6 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Terminated No phase listed Observational

Thrombin Generation and Thromboelastography in Non-overt DIC

NCT00299949
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting No phase listed Observational

A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)

NCT07582276
View directory record Official record
Conditions
Hemophilia a
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
30 Years to 50 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thrombin Regulated Platelet Activation

NCT00855296
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 23, 2026, 8:45 AM EDT
Terminated Phase 1 Interventional

Vascular Sealant Study

NCT00618358
View directory record Official record
Conditions
Arteriovenous Access Grafts or Extra-anatomic and Infra-inguinal Grafts
Interventions
Vascular Sealant System, Gelfoam/Thrombin
Device · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Timeline
Started 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 4 Interventional

Hemostatic Matrix in Endoscopic Sinus Surgery

NCT00242437
View directory record Official record
Conditions
Sinusitis
Interventions
Hemostatic matrix, bovine thrombin
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2005 – 2006
U.S. locations
3
States / cities
Summit, New Jersey • Charleston, South Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Oct 23, 2026, 8:45 AM EDT
Withdrawn No phase listed Observational

VALIDATE: Factor VIII Trending for MS Relapse

NCT04082468
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood sample collection for coagulation profile
Diagnostic Test
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 23, 2026, 8:45 AM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients

NCT02433210
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
ELISIO-15H, Revaclear, Optiflux
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 2Phase 3 Interventional

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

NCT04924322
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

NCT03725098
View directory record Official record
Conditions
Cardiothoracic Surgery
Interventions
HEMOBLAST Bellows, FLOSEAL
Device
Lead sponsor
Biom'Up France SAS
Industry
Eligibility
Not listed
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Los Angeles, California • Honolulu, Hawaii • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

NCT00043940
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Thrombosis
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 23, 2026, 8:45 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

NCT04814433
View directory record Official record
Conditions
Opioid Pain Medication
Interventions
Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

GATT-Patch Versus TachoSil in Liver Surgery

NCT05385952
View directory record Official record
Conditions
Intraoperative Bleeding, Hemorrhage, Surgical, Liver Diseases
Interventions
GATT-Patch (currently named ETHIZIA), TachoSil
Device · Drug
Lead sponsor
GATT Technologies BV
Industry
Eligibility
22 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Los Angeles, California • St Louis, Missouri • Newark, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Results available

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NCT01848899
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 23, 2026, 8:45 AM EDT